Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Autor: Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)

Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment

Externí odkaz: https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f

Psychological impacts of COVID-19 pandemic in cancer patients on active treatment

Autor: Sinan Koca, Esra Koca, Ilker N. Okten, Fatma FC. Orengül, Akın Oztürk, Melike Ozçelik, Abdilkerim Oyman, Ibrahim Çil, Mahmut Gümüş

Publikováno v: Heliyon, Vol 8, Iss 8, Pp e10142- (2022)

Introduction: Although cancer patients have a high risk of exposing COVID-19 and developing severe complications, they have to receive active treatment. We aimed to determine the psychological conditions of cancer patients and shed light on the estab

Externí odkaz: https://doaj.org/article/3fa24aa1639848028cdd6693471cf0a2

Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Autor: Tuğba Başoğlu, Abdullah Sakin, Cihan Erol, Ercan Özden, Devrim Çabuk, Ebru Çılbır, Deniz Tataroğlu Özyükseler, Murat Ayhan, Mehmet Ali Şendur, Mutlu Dogan, Berna Öksüzoğlu, Melek Karakurt Eryılmaz, Özlem Er, Elif Şenocak Taşçı, Neslihan Özyurt, Özgecan Dülgar, Miraç Özen, İlhan Hacıbekiroğlu, İrem Öner, Esma Türkmen Bekmez, Hasan Çağrı Yıldırım, Şuayib Yalçın, Semra Paydaş, Emre Yekedüz, Asude Aksoy, Melike Özçelik, Abdilkerim Oyman, Elvina Almuradova, Bülent Karabulut, Nazan Demir, Murat Dinçer, Nuriye Özdemir, Dilek Erdem, Naziye Ak, Ali İnal, Derya Kıvrak Salim, Gülhan İpek Deniz, Teoman Şakalar, Ahmet Gülmez, Turgut Kaçan, Özlem Özdemir, Özkan Alan, Çağlar Ünal, Yusuf Karakaş, Serdar Turhal, Perran Fulden Yumuk

Publikováno v: Journal of Chemotherapy. 35:142-149

Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1c2284ea2d913751fc2b471ed5ebfcc
https://doi.org/10.1080/1120009x.2022.2073159

Effects of Cytoreductive Nephrectomy on Nivolumab Outcomes in Patients with Metastatic Clear Cell Renal Carcinoma: A Retrospective Observational Real-Life Data of Turkish Oncology Group

Autor: Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, Mustafa Korkmaz, Dilek Erdem, Umut Cakıroglu, Mustafa Karaca, Ahmet Dirican, Omer Fatih Olmez, Sabin Göktaş Aydın, Ali Gökyer, Ahmet Küçükarda, Ahmet Gülmez, Perran Fulden Yumuk, Nazim Can Demircan, Abdilkerim Oyman, Teoman Sakalar, Fatih Karataş, Hacer Demir, Ayse Irem Yasin, Adem Deligönül, Bahar Dakiki, Mehmet Refik Goktug, Okan Avcı, Seher Yildiz Tacar, Nazım Serdar Turhal, Gulhan Ipek Deniz, Turgut Kacan, Erdem Cubukcu, Türkkan Evrensel

Renal cell carcinoma is the fourteenth most common cancer in the world with a male to female ratio of 2:1, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Nivolumab is preferred as subsequent therapy in patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e5a15870b5d76209b99a5b795b3e4bc
https://doi.org/10.21203/rs.3.rs-1693977/v1

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Autor: Cihan, Erol, Abdullah, Sakin, Tuğba, Başoğlu, Ercan, Özden, Devrim, Çabuk, Mutlu, Doğan, Berna, Öksüzoğlu, Hasan Çağrı, Yıldırım, İrem, Öner, Melek Karakurt, Eryılmaz, Özgecan, Dülgar, Dinçer, Aydın, Neslihan, Doğan, Miraç, Özen, İlhan, Hacıbekiroğlu, Nuriye, Özdemir, Fatih, Gürler, Nail, Paksoy, Senem, Karabulut, Asude, Aksoy, Mutlu, Hızal, Seda, Kahraman, Erdem, Şen, Semra, Paydaş, Ebru, Çılbır, Feyza, Fırat, Nadiye, Akdeniz, Melike, Özçelik, Abdilkerim, Oyman, Naziyet Köse, Baytemür, Ramazan, Acar, Elvina, Almuradova, Bülent, Karabulut, Teoman, Şakalar, Hacı, Arak, Ezgi, Değerli, Sema, Türker, Özkan, Alan, Özlem, Er, Elif Şenocak, Taşçı, Nazan, Demir, Eyyüp, Çavdar, Serdar, Turhal, Didem Şener, Dede, Muhammed Bülent, Akıncı, Bülent, Yalçın, Fulden, Yumuk, Şuayib, Yalçın, Mehmet Ali Nahit, Şendur

Publikováno v: Turkish journal of medical sciences. 52(4)

Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in real-life gastric and GEJ tumors.The data of pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7a9dcc4581150474c11fcd346cfe9c89
https://pubmed.ncbi.nlm.nih.gov/36326360